Amedisys Inc
AMEDDelisted Aug 14, 2025- Industry
- Services-Home Health Care Services
- SEC CIK
- 0000896262
Amedisys Inc was delisted on Aug 14, 2025; its insiders filed their last Form 4 on Aug 14, 2025; 321 institutions reported holding it in 13F filings for Q2 2025, worth $3.20B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 11:52 AM ET
Revenue flow, FY2024
Where the revenue went in FY2024, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2025 | Feb 21, 2024 | Feb 15, 2023 | Feb 23, 2022 | Feb 24, 2021 |
| Revenue | $2.35B | – | – | – | – |
| Cost of revenue | $1.33B | $1.25B | $1.26B | $1.23B | $1.19B |
| Selling, general and administrative | $856.8M | $816.8M | $754.1M | $711.2M | $668.2M |
| Operating income | $94.5M | $156.4M | $180.8M | $251.9M | $219.3M |
| Interest expense | – | $31.3M | $22.2M | $9.53M | $11.0M |
| Income tax | $48.1M | $50.6M | $42.5M | $70.1M | $25.6M |
| Net income | $43.2M | -$9.75M | $118.6M | $209.1M | $183.6M |
| EPS, basic | $1.32 | $-0.30 | $3.65 | $6.41 | $5.64 |
| EPS, diluted | $1.31 | $-0.30 | $3.63 | $6.34 | $5.52 |
| Weighted shares, basic | 32.7M | 32.6M | 32.5M | 32.6M | 32.6M |
| Weighted shares, diluted | 33.1M | 32.6M | 32.7M | 33.0M | 33.3M |
| Margins and growth | |||||
| Operating margin | 4.0% | – | – | – | – |
| Net margin | 1.8% | – | – | – | – |
| Net income growth, year over year | – | −108.2% | −43.3% | +13.9% | +44.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2025 | Feb 21, 2024 | Feb 15, 2023 | Feb 23, 2022 | Feb 24, 2021 |
| Cash and equivalents | $303.2M | $126.5M | $40.5M | $42.7M | $81.8M |
| Accounts receivable | $296.1M | $313.4M | $296.8M | $275.0M | $255.1M |
| Total current assets | $632.1M | $496.9M | $389.0M | $356.7M | $362.0M |
| Property, plant and equipment | $42.1M | $41.8M | $16.0M | $18.4M | $23.7M |
| Goodwill | $1.21B | $1.24B | $1.29B | $1.20B | $932.7M |
| Intangible assets | $81.2M | $102.7M | $101.2M | $111.2M | $74.2M |
| Total assets | $2.14B | $2.06B | $1.98B | $1.86B | $1.57B |
| Accounts payable | $40.0M | $28.2M | $43.7M | $38.2M | $42.7M |
| Short-term debt | $38.0M | $36.3M | $15.5M | $13.0M | $10.5M |
| Total current liabilities | $514.4M | $473.7M | $355.5M | $374.3M | $456.3M |
| Long-term debt | $339.3M | $361.9M | $419.4M | $432.1M | $204.5M |
| Total liabilities | $958.7M | $940.4M | $869.7M | $880.6M | $756.5M |
| Shareholders' equity | $1.18B | $1.12B | $1.11B | $976.3M | $810.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2025 | Feb 21, 2024 | Feb 15, 2023 | Feb 23, 2022 | Feb 24, 2021 |
| Operating cash flow | $221.7M | $137.2M | $133.3M | $188.9M | $289.0M |
| Capital expenditures | $6.55M | $5.62M | $6.17M | $6.30M | $5.33M |
| Free cash flow | $215.1M | $131.6M | $127.1M | $182.6M | $283.6M |
| Depreciation and amortization | $26.0M | $23.8M | $24.9M | $30.9M | $28.8M |
| Stock-based compensation | $30.6M | $29.0M | $16.6M | $23.8M | $26.7M |
| Share buybacks | $0 | $0 | $17.4M | $99.9M | $0 |
| Investing cash flow | -$8.36M | $35.1M | -$94.5M | -$281.6M | -$287.1M |
| Financing cash flow | -$48.9M | -$87.5M | -$30.4M | $55.1M | -$15.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.3% | – | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.